[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA55508A - Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules - Google Patents

Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules

Info

Publication number
MA55508A
MA55508A MA055508A MA55508A MA55508A MA 55508 A MA55508 A MA 55508A MA 055508 A MA055508 A MA 055508A MA 55508 A MA55508 A MA 55508A MA 55508 A MA55508 A MA 55508A
Authority
MA
Morocco
Prior art keywords
osimertinib
treatment
lung cancer
small cell
cell lung
Prior art date
Application number
MA055508A
Other languages
English (en)
Inventor
Anthony Francis Patrick Nash
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA55508A publication Critical patent/MA55508A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA055508A 2019-03-29 2020-03-27 Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules MA55508A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962825867P 2019-03-29 2019-03-29

Publications (1)

Publication Number Publication Date
MA55508A true MA55508A (fr) 2022-02-09

Family

ID=70224330

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055508A MA55508A (fr) 2019-03-29 2020-03-27 Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules

Country Status (11)

Country Link
US (1) US20220175783A1 (fr)
EP (1) EP3946346A1 (fr)
JP (1) JP2022526159A (fr)
KR (1) KR20210144844A (fr)
CN (1) CN113645976A (fr)
AU (2) AU2020250832A1 (fr)
CA (1) CA3133766A1 (fr)
EA (1) EA202192552A1 (fr)
MA (1) MA55508A (fr)
MX (1) MX2021011810A (fr)
WO (1) WO2020201097A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240050441A1 (en) * 2020-12-11 2024-02-15 Erasca, Inc. Combination therapies for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1746999T3 (pl) 2004-05-06 2012-07-31 Warner Lambert Co 4-fenyloaminochinazolin-6-yloamidy
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
PE20141700A1 (es) 2011-07-27 2014-11-20 Astrazeneca Ab Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
MX362247B (es) 2013-03-06 2019-01-09 Astrazeneca Ab Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico.
US20150152508A1 (en) * 2013-09-30 2015-06-04 Daiichi Sankyo Company, Limited Nucleic acid biomarker and use thereof
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
EP3142697A1 (fr) * 2014-05-15 2017-03-22 Bristol-Myers Squibb Company Traitement du cancer du poumon à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un autre agent anticancéreux
KR102662358B1 (ko) 2014-10-13 2024-04-30 주식회사유한양행 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
AU2016251971A1 (en) * 2015-04-23 2017-12-07 Medimmune Limited Combination therapy for non-small cell lung cancer positive for EGFR mutation
US10813933B2 (en) * 2016-05-17 2020-10-27 Japanese Foundation For Cancer Research Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
EP3585389A4 (fr) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. Traitement du cancer entraîné par egfr avec moins d'effets secondaires

Also Published As

Publication number Publication date
MX2021011810A (es) 2021-10-26
WO2020201097A1 (fr) 2020-10-08
CA3133766A1 (fr) 2020-10-08
CN113645976A (zh) 2021-11-12
EA202192552A1 (ru) 2021-12-17
US20220175783A1 (en) 2022-06-09
JP2022526159A (ja) 2022-05-23
AU2023233122A1 (en) 2023-10-05
KR20210144844A (ko) 2021-11-30
EP3946346A1 (fr) 2022-02-09
AU2020250832A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
MA51823A (fr) Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
MA45073A (fr) Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers
MA51762A (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du poumon, y compris le cpnpc et d'autres cancers
MA41805A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
MA45122A (fr) Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
MA52886A (fr) Composés de purinone et leur utilisation dans le traitement du cancer
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA49760A (fr) Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique
MA42494A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA45046A (fr) Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA43163A (fr) Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
MA47450A (fr) Sulfinylpyridines et leur utilisation dans le traitement du cancer
DK3416957T3 (da) 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
MA47452A (fr) Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer
MA47458A (fr) Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer
DK3860990T3 (da) Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer
MA47451A (fr) Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
MA52627A (fr) Traitement du cancer
MA45848A (fr) Cobicistat destiné à être utilisé dans des traitements du cancer
MA55507A (fr) Macitentan destiné à être utilisé dans le traitement de l'hypertension portopulmonaire